[Intrarectal povidone-iodine to reduce the risk of genitourinary infections after transrectal prostate biopsy]

Rev Med Inst Mex Seguro Soc. Nov-Dec 2015;53(6):728-31.
[Article in Spanish]

Abstract

Background: The aim of this study is to compare two different preparations in patients undergoing transrectal prostate biopsies samples (TPBS) and assess the prevalence of genitourinary infections (GUI).

Methods: A historical cohort of patients undergoing TBPS for suspected prostate cancer. Two groups were compared: one with endorectal lubricant jelly and another with the addition of a povidone-iodine lubricating jelly. Complications were evaluated at three weeks. A bivariate analysis was performed by calculating the OR (95 % CI) to determine if the additional endorectal povidone-iodine pre-TBPS reduced GUI and other complications.

Results: 185 patients (Group I n = 86, Group II n = 96) were evaluated. 45 and 25 % had genitourinary tract infection (OR: 0.4, CI: 0.2-0.9, p = 0.004); fever was presented in 21 and 10 % respectively (OR: 0.42, CI: 0.1-0.9, p = 0.04).

Conclusions: A reduction was observed in the presence of genitourinary infections in patients who had intrarectal povidone-iodine preparation applied.

Introducción: el objetivo de este estudio es comparar dos preparaciones distintas en pacientes sometidos a la toma de biopsias prostáticas transrectales (BPTR) y evaluar la prevalencia de infecciones genitourinarias (IGU). Métodos: se compararon dos grupos de pacientes con sospecha de cáncer de próstata sometidos a Biopsia Prostática Transrectal (BPTR): Con jalea lubricante endorrectal (grupo l, cohorte histórica) y con jalea lubricante más iodopovidona (grupo II, cohorte prospectiva). Se evaluaron las complicaciones a las tres semanas. Se realizó un análisis bivariado, calculando su OR (IC: 95 %) para determinar si la iodopovidona endorrectal adicional previa a la BPTR disminuye las IGU y otras complicaciones. Resultados: Se evaluaron 185 pacientes (Grupo I n = 86; grupo II n = 96). Tuvieron infección del tracto genitourinario el 45 y 25 % (OR: 0.4, IC: 0.2-0.9, p = 0.004); la fiebre se presentó en el 21 y 10 % respectivamente (OR: 0.42, IC: 0.1-0.9, p = 0.04). Conclusiones: Se observó una reducción en la presencia de infecciones genitourinarias en pacientes a quienes se aplicó en su preparación iodopovidona intrarrectal.

Keywords: Biopsy; Povidone-Iodine; Prostate; Urinary tract.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Administration, Rectal
  • Aged
  • Anti-Infective Agents, Local / administration & dosage*
  • Anti-Infective Agents, Local / therapeutic use
  • Biopsy
  • Genital Diseases, Male / epidemiology
  • Genital Diseases, Male / etiology
  • Genital Diseases, Male / prevention & control*
  • Humans
  • Male
  • Middle Aged
  • Povidone-Iodine / administration & dosage*
  • Povidone-Iodine / therapeutic use
  • Prospective Studies
  • Prostate / pathology*
  • Prostatic Neoplasms / pathology
  • Treatment Outcome
  • Urinary Tract Infections / epidemiology
  • Urinary Tract Infections / etiology
  • Urinary Tract Infections / prevention & control*

Substances

  • Anti-Infective Agents, Local
  • Povidone-Iodine